Lilly Q2 revenue $6.74B (+23% YoY); non-GAAP EPS $1.87 (+29%); updates 2021 guidance

ELI LILLY & Co

2021-Q2 EPS reported $3.01 revenue$13,545,700,000

Revenue $6.74B (+23% YoY); volume growth 22%; non-GAAP EPS $1.87 (+29% YoY).
Reported EPS $1.53 (-1% YoY) due to $423M COVID antibody inventory charge.
2021 GAAP EPS guidance updated to $6.73-$6.93; non-GAAP unchanged at $7.80-$8.00.
Key products: Trulicity +25%, Taltz +44%, Verzenio +64%; pipeline milestones for tirzepatide, Jardiance, donanemab.
Board authorizes $5B share repurchase; acquires Protomer; global collaboration with MiNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.